AVE(SH:688067) Zheng Quan Shi Bao Wang·2025-10-21 12:45Core Viewpoint - Awei Technology plans to invest 10 million yuan in Hunan Luying Technology Co., Ltd., marking its entry into the high-end nuclear medicine imaging equipment sector [1][2]. Investment Details - Awei Technology will invest 10 million yuan, participating in a total capital increase of 30 million yuan alongside other investors [1]. - After the investment, Awei Technology will hold a 9.07% stake in Luying Technology [1]. - The investment decision was made within the general manager's approval authority, requiring no board or shareholder meeting approval [1]. Company Background - Luying Technology, established on April 29, 2025, focuses on the development of domestic high-resolution single-photon emission computed tomography (SPECT) and its core components [1][3]. - The company aims to provide precise, safe, economical, and convenient molecular imaging diagnostic solutions [3]. Market Context - The global medical imaging and radiotherapy equipment market is experiencing rapid and stable growth [2]. - Government policies are promoting the domestic production of nuclear medicine imaging equipment, supporting the industry's development [2]. Product and Technology Insights - SPECT/CT is recognized for its clinical value in early diagnosis and evaluation of tumors, as well as its importance in cardiovascular, bone, and neurological imaging [2]. - Luying Technology's project team has experience in obtaining regulatory approval for SPECT/CT devices and holds core intellectual property, positioning it at an advanced level domestically [3]. Management and Ownership - The controlling shareholders of Luying Technology include key figures from Hunan University, indicating a strong academic and technical foundation [3]. - The company currently has no sales revenue and is still in the product development phase, which presents uncertainties regarding future profitability [3].